Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Julian Ngo

MOHS-Micrographic Surgery Carlisle, PA Doctor of Osteopathy

NPI 1689989675 CMS profile 212860

19 Sprint Dr, Suite 1, Carlisle, PA 17015

Open in the dashboard

General payments

$5,117

237 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Julian Ngo of Carlisle, PA is reported in the CMS Open Payments database as having received $5,117 across 237 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 75th percentile of MOHS-Micrographic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $868 31
2024 General $911 33
2023 General $873 37
2022 General $632 36
2021 General $674 40
2020 General $376 20
2019 General $783 40

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Julian Ngo
  • MOHS-Micrographic Surgery median
  • Middle half of MOHS-Micrographic Surgery
  • National median

In program year 2025, general payments to Julian Ngo were reported at $868. Among 1,077 MOHS-Micrographic Surgery profiles paid that year, the median was $465 and the middle half received between $145 and $1,066.

Show as a table
Year Julian Ngo MOHS-Micrographic Surgery median Middle half National median
2019 $783 $316 $106–$785 $163
2020 $376 $162 $68–$412 $114
2021 $674 $243 $87–$654 $132
2022 $632 $300 $102–$887 $149
2023 $873 $364 $125–$1,010 $160
2024 $911 $445 $142–$1,108 $164
2025 $868 $465 $145–$1,066 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $998 60 payments
  2. Janssen Biotech, Inc. $673 21 payments
  3. Pfizer Inc. $439 25 payments
  4. Sun Pharmaceutical Industries Inc. $435 15 payments
  5. Novartis Pharmaceuticals Corporation $350 17 payments
  6. UCB, Inc. $348 14 payments
  7. Regeneron Healthcare Solutions, Inc. $331 10 payments
  8. Genzyme Corporation $281 13 payments
  9. Ortho Dermatologics, a division of Bausch Health US, LLC $280 11 payments
  10. Amgen Inc. $216 10 payments
  11. Other $766 41 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,603 230 payments
  2. Education $514 7 payments
Products named General payments · program years 2019–2025
  1. TREMFYA $654 20 payments
  2. SKYRIZI $435 32 payments
  3. RINVOQ $403 19 payments
  4. EUCRISA $330 19 payments
  5. DUPIXENT Inflammation And Immunology $306 9 payments
  6. DUPIXENT Immunology $252 11 payments
  7. Bimzelx $225 9 payments
  8. CIBINQO $216 11 payments
  9. DUOBRII $212 6 payments
  10. BRYHALI $200 6 payments
  11. Other $2,516 120 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 27 drugs

Part D claims

1,157

Median for Dermatology: 534

Drug cost

$895,151

Median for Dermatology: $67,151

Branded share of claims

10.8%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Skyrizi Pen Risankizumab-Rzaa Brand 19 $396,877
Otezla Apremilast Brand 35 $166,378
Dupixent Pen Dupilumab Brand 26 $112,663
Humira Pen Adalimumab Brand 14 $106,317
Dupixent Syringe Dupilumab Brand 19 $72,013
Clobetasol Propionate Generic 205 $11,680
Calcipotriene Generic 50 $8,295
Tacrolimus Generic 28 $3,863
Desonide Generic 45 $2,814
Ketoconazole Generic 114 $2,404

The 10 drugs with the highest cost, of 27 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 87 billing codes

Paid by Medicare

$631,223

Of which drugs: $11,878

Medicare patients

2,207

Average age 75

Services billed

11,318

1,279 women, 928 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 68%
Arthritis 44%
Ischemic heart disease 24%
Diabetes 20%
Chronic kidney disease 19%
Osteoporosis 18%
Depression 15%
Cancer 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) J7308 Office 30 39 $11,878

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $201
$201 45 —
SOTYKTU
  • E.R. Squibb & Sons, L.L.C. $128
$128 — —
TREMFYA
  • Janssen Biotech, Inc. $126
$126 — —
RINVOQ
  • AbbVie, Inc. $123
$123 — —
SKYRIZI
  • AbbVie, Inc. $96
$96 19 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

237 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other MOHS-Micrographic Surgery in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record